Survival and Response Outcomes for Gastrointestinal Neuroendocrine Tumor (GEP-NETs) Patients Treated with Lutetium-177-DOTATATE in a Brazilian Reference Center: A Six-Year Follow-Up Experience.

Zenaide Silva de Souza,Camila Bragança Xavier,Luciana Beatriz Mendes Gomes,Maria Fernanda Barbosa de Medeiros,Micelange Carvalho de Sousa,Allan Andresson Lima Pereira,José Flávio Gomes Marin,Carlos Alberto Buchpiguel,Frederico Perego Costa

Cancers（2023）

引用 0|浏览10

暂无评分

摘要

PRRT provides long-term PFS in patients with G1/G2 GEP-NETs independent of clinical characteristics and primary site. G3 has worse survival, but selected patients may experience long OS after PRRT treatment.

查看译文

关键词

neuroendocrine tumors, lutetium-177, nuclear medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要